NCT01421940

The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Kyungpook National University Hospital · Academic / Other
• Sex: Male
• Age: 20 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Sexual dysfunctions are well-recognized complications after rectal cancer surgery. Damage to the pelvic plexus and pelvic splanchnic nerves results in ejaculatory dysfunction. The purpose of this study is to evaluate the efficacy of Udenafil(Zydena®, Dong-A Pharmaceutical co., Ltd, Seoul, Korea) in penile rehabilitation for patients who undertake total mesorectal excision.

Conditions

• Rectal Cancer

Interventions

Type	Name	Description
DRUG	Placebo drug	After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
DRUG	Udenafil	After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.

Timeline

• Start date: 2009-10-01
• Primary completion: 2011-12-01
• Completion: 2013-10-01
• First posted: 2011-08-23
• Last updated: 2015-03-10

Locations

1 site across 1 country: South Korea